Adriana Martín

Learn More
Every day more and more users with different abilities and/or temporally or permanent disabilities are accessing the Web, and many of them have difficulties in reaching the desired information. However, the development of this kind of software is complicated for several reasons. Though some of them are technological, the majority are related with the need(More)
Usually, a huge number of tools and proposals help developers assess Accessibility of Web applications; however, looking from the designer perspective, there is no such a similar situation. It seems that creating accessible Web sites is more expensive and complicated than creating Web sites and then assessing/modifying them. Although this feeling may be(More)
OBJECTIVE The objective of this study is to evaluate the economic benefits of immunoglobulin replacement therapy achieved subcutaneously (subcutaneous immunoglobulin, SCIG) by the rapid push method compared to intravenous infusion therapy (intravenous immunoglobulin, IVIG) in primary immune deficiency (PID) patients from the healthcare system perspective in(More)
The design and synthesis of enhanced membrane-intercalating biomaterials for drug delivery or vascular membrane targeting is currently challenged by the lack of screening and prediction tools. The present work demonstrates the generation of a Quantitative Structural Activity Relationship model (QSAR) to make a priori predictions. Amphiphilic macromolecules(More)
Objectives To assess the safety and efficacy of Hizentra™, a 20% human IgG for subcutaneous administration, in a cohort of patients with primary immunodeficiency disorders (PID) after a dose equivalent switch from their previous treatment. Methods A cohort study of 57 PID patients was reviewed 3 months post-transition to the 20% Subcutaneous Immunoglobu-lin(More)
Background Primary immune deficiencies (PID) are genetic disorders resulting in recurrent infections. Immunoglobulin replacement therapy in PID patients can be achieved intravenously (IVIG) or subcutaneously (SCIG) with similar efficacy and safety profiles but with different resource use and associated costs. Methods SCIG and IVIG options for immunoglobulin(More)